Brief: Hansa Says Total Revenue In Q3 Is SEK 22.8 Million

Hansa Biopharma AB

11/10/2023 17:44

Oct 11 (Reuters) - Hansa Biopharma AB  HNSA.ST :
    * UPDATE ON CONFIDES PHASE 3 TRIAL OF IMLIFIDASE IN HIGHLY
SENSITIZED KIDNEY TRANSPLANT PATIENTS
    * BIOLOGIC LICENSE APPLICATION SUBMISSION EXPECTED FOR 2025
    * TOTAL REVENUE IN Q3 IS SEK 22.8 MILLION
    * HANSA-NEW SUPPLY AGREEMENTS WITH TRANSPLANT CENTERS IN
EUROPE
SECURED, EXPECTED TO TRANSLATE INTO INCREASED COMMERCIAL SALES
IN Q4, PERIODS TO COME

Source text for Eikon:  ID:nWkr19z1XN 
Further company coverage:  HNSA.ST 

 ((Reuters.Briefs@thomsonreuters.com;))